Skip to Content
  • Previous Rank
    186
  • Revenues ($M)
    $52,824
  • Revenue Percent Change
    8.1%
  • Profits ($M)
    $7,215
  • Profits Percent Change
    3.7%
  • Assets ($M)
    $171,615
  • Employees
    96,500

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Ian C. Read
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, NY
Websitehttp://www.pfizer.com
Years on Global 500 List23
Employees96,500

Pfizer Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,2153.7%
Assets ($M)$171,615-
Total Stockholder Equity ($M)$59,544-

Profit Ratios

Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%